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Summary
Objectives: To evaluate the efﬁcacy of treatment of drooling by ultrasound-guided botulinum
toxin injection of the salivary glands and to determine the optimal modalities of this procedure.
Patients and methods: This study is a retrospective review of patients treated for drooling
by injection of 100 units of Botox® into the parotid and submaxillary glands between 2002 and
2008. Efﬁcacy was evaluated by a quality of life questionnaire six weeks after the injections.
Results: One hundred and eleven injection sessions were performed in 70 patients aged one to
84 years with a beneﬁcial effect in 66% of cases. The most effective protocol was injection of
20 units of botulinum toxin into each submaxillary gland and 30 units of toxin into each parotid
gland.
Conclusion: The treatment of drooling by Botox® injections into salivary glands is effective.
The authors propose ultrasound-guided injection of both submaxillary glands and both parotid
glands. These injections can be repeated in the case of recurrence of drooling.
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rooling is deﬁned as oral incontinence of saliva secreted in
ormal quantities and with normal quality [1]. It differs from
ypersialorrhoea, which corresponds to increased salivary
ecretion. This symptom, responsible for psychosocial and
hysical morbidity, is observed in adults with neurological
iseases such as amyotrophic lateral sclerosis, Parkinson’s
isease [2,3], sequelae of stroke or brain surgery and head
njuries. Drooling is also observed in patients with seque-
ae of head and neck surgery. In children, drooling is mainly
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bserved in patients with cerebral palsy (33% of patients
ith cerebral palsy present drooling [4]).
The use of systemic anticholinergic agents [2], atropine
nd scopolamine, is effective but contraindicated in
atients with glaucoma, obstructive uropathy and myas-
henia gravis. These treatments, available in the form of
copolamine patches or sublingual atropine drops, have
recognized but limited efﬁcacy due to poor adherence
o treatment. Finally, radiotherapy is reserved for elderly
atients [5] presenting contraindications to oral treatment
r surgery. Surgical treatment by resection of the main
alivary glands, ligation or transposition of salivary ducts
6] is proposed after failure of other treatments. Parotid
enervation, by tympanic neurotomy via the external audi-
ory meatus, has also been described, but has now been
bandoned. Botulinum toxin injection of the submaxil-
served.
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pUltrasound-guided botulinum toxin injections for treatment
lary and parotid glands has been proposed since 1997 [7].
Pharmacologically, botulinum toxin blocks the release of
acetylcholine into the neuromuscular synapse, thereby
decreasing salivary secretion [8].
This study was designed to evaluate the efﬁcacy of this
treatment and to determine the practical modalities of this
procedure.
Patients and methods
This retrospective study was conducted on all patients
treated by one or several botulinum toxin (Botox®) injection
sessions between May 2002 and February 2008. All patients
or their legal guardians were informed about the absence of
marketing authorisation for botulinum toxin A, Botox® for
the treatment of drooling and accepted the principle of this
treatment. The patient information speciﬁed that Botox®
injections were designed to reduce salivary secretion, with-
out completely stopping drooling. Various protocols were
applied as a function of the patient and the time at which
the injections were performed. The total dose of botulinum
toxin injected in every case was 100mU (mouse units)
diluted in 2mL of physiological saline. The number of injec-
tions and the dose injected per gland differed according
to the various protocols. The dose in children was 5mU/kg
without exceeding a total dose of 100mU.
The injection was performed without anaesthesia in
adults and under general anaesthesia in children. After dis-
infection of the skin and the ultrasound transducer (high
frequency linear transducer > 7.5MHz), a sterile ultrasound
gel was applied to the skin. The ﬁrst phase consisted of pre-
cise location of the gland to be injected by the radiologist.
An Anestago® needle (needles having side-holes) was then
introduced perpendicularly to the ultrasound transducer.
Botulinum toxin was injected under ultrasound guidance and
a second injection, away from the ﬁrst, was sometimes per-
formed in the same gland. After removing the needle, the
salivary gland was massaged to facilitate diffusion of the
product.
Efﬁcacy of the injections was evaluated by a systematic
telephone interview of the patient or a relative, six to eight
weeks after the injection. Questions concerned changes in
the number of handkerchiefs used to wipe the patient’s
mouth, the need to change clothes, changes in the level of
comfort, whether or not another injection would be desired,
and the overall efﬁcacy perceived by the patient and the
family. A scoring system was based on this clinical interview:
• 0: no efﬁcacy;
• 1: partial efﬁcacy (persistence of minimal drooling,
partial improvement of quality of life, insufﬁcient
improvement in relation to the patient’s expectations);
• 2: good efﬁcacy but of brief duration (< 1month);
• 3: very effective: resolution of drooling and the discom-
fort experienced by the patient;
• 4: unknown (patient died or lost to follow-up).Results
Seventy patients between the ages of one and 84 years
(29 females and 41males) were included. A total of
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11 injection sessions were performed, as some patients
ere treated several times. The diseases most frequently
ssociated with drooling were amyotrophic lateral sclero-
is (ALS), Parkinson’s disease and cerebral palsy. Causes
f cerebral palsy, other than neonatal causes, were Rett
yndrome, epileptic encephalopathy and brain tumours.
atients treated for surgical sequelae had been operated
y total pharyngolaryngectomy in two cases, supracricoid
aryngectomy in two cases and supraglottic laryngectomy
n one case. Most patients received a single injection ses-
ion (65%) and 24% of patients received a second injection
ession. These data are summarized in Table 1.
Table 2 presents the distribution of the 100 units of
otulinum toxin between the various salivary glands accord-
ng to the various injection protocols. Seven protocols were
sed, comprising variable numbers of injection sites and
ariable doses in each parotid and submaxillary gland.
No efﬁcacy was observed in 25.4% of cases (score 0).
artial efﬁcacy was observed in 22.5% of cases (score 1),
rief efﬁcacy was observed in 1.8% of cases (score 2) and
ery good efﬁcacy was observed in 42.3% of cases (score 3).
ineteen injections could not be evaluated (patient lost to
ollow-up, dead or impossible evaluation). Good and partial
fﬁcacy of injections according to the protocol used and the
nderlying disease is presented in Table 3. A second injec-
ion session was performed in 38 patients, with good efﬁcacy
n 51.8% of cases and partial efﬁcacy in 22.2% of cases. No
ajor complication was observed (haematoma of the ﬂoor
f the mouth or paralysis).
Comparison of these results with published literature,
erived from all 19 studies based on more than 10 patients
onducted between 1997 to 2007, is presented in Table 4.
iscussion
otulinum toxin injection of the salivary glands to reduce
rooling is widely indicated in certain neurological diseases
9—11]. A review of the indications in the various published
tudies shows that botulinum toxin is mainly used in children
ith cerebral palsy (30%), patients with Parkinson’s disease
20%) and patients with amyotrophic lateral sclerosis (15%)
12]. There is a general consensus concerning the efﬁcacy
f this treatment in these diseases [12] and this treatment
as effective in 66.6% of cases in the present study.
In more than half of the published studies, only the
arotid glands were injected, while only the submaxillary
lands were injected in 9.5% of studies and both glands were
njected in 38% of studies. The submaxillary gland is the
ain gland responsible for resting saliva secretion, while
he parotid gland is predominantly active during mastication
13]. We therefore propose systematic injection of all four
lands in order to reduce permanent drooling and drooling
uring meals.
Twenty of the 41 studies published in the literature
ere performed with ultrasound guidance, while the other
uthors used anatomical detection of the gland based on pal-
ation. Only one study compared these two methods: Dogu
t al. [14] showed that ultrasound guidance provided bet-
er results. In agreement with this author, we consider that
ystematic ultrasound guidance of injections is essential,
s it provides good visualization of the injection site and
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Table 1 Series of 70 treated patients.
Diseases n % Age F/M Number of sessions
1 2 3 4 5
Amyotrophic lateral sclerosis 25 36 [42—81] 17/8 20 4 1 0 0
Parkinson’s disease 14 20 [53—82] 4/10 5 7 2 0 0
Cerebral palsy 15 21.5 [1—40] 5/10 7 3 3 2 0
Steinert’s disease 2 2.5 [36—67] 0/2 1 0 0 0 1
Head injury 9 13 [17—84] 2/7 6 3 0 0 0
Surgical sequelae 5 7 [55—69] 1/4 4 0 1 0 0
Total 70 [1—84] 29/41 43 17 7 2 1
Table 2 Distribution of 111 sessions of injection in seven protocols.
Doses and number of injections by side Protocol n (%)
Parotid (mU) Submaxillary (mU)
20 30 0 5 (4.5)
30 20 1 2 (1.8)
2× 15 20 2 56 (50.4)
20 2× 15 3 24 (21.6)
2× 7.5 10 4 2 (1.8)
2× 20 10 5 7 (6.3)
25 25 6 15 (13.5)
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iffusion of the toxin in the gland, thereby avoiding acci-
ental injection into adjacent muscles, which constitutes
rare but serious complication of treatment. No serious
dverse effects were observed in the present series. The
nly minor adverse effects were swollen glands following
he injection, thicker saliva and mainly pain during injec-
ion. Many authors use lidocaine cream for local anaesthesia
n adults and general anaesthesia in children to avoid the
ain of injection. In the present series, all children under
he age of 15 years were treated under general anaesthesia,
ut local anaesthesia did not appear to be useful in adults,
s pain is due to injection of the gland rather than skin
ffraction.
In this series, botulinum toxin injections were considered
o be very effective in 42.3% of cases and partially effec-
ive in 22.5% of cases. The efﬁcacy of the various injection
rotocols could not be compared statistically due to the
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Table 3 Good and partial efﬁcacy according to the underlying di
Protocol P0 P1 P2
Number of injections (5) (2) (56
ALS (31) — — 68.
Parkinson’s disease (25) 50% 100% 77%
Cerebral palsy (30) 100% 0% 75%
Steinert’s disease (6) — — 75%
Stroke/head injury (12) 0% — 66.
Surgical sequelae (7) — — 100
ALS: Amyotrophic lateral sclerosis.eterogeneous populations in each group. Published series
re also based on relatively small sample sizes, prevent-
ng statistical comparison of the various injection protocols.
owever, in the present series, based on a large sample size
70 patients), the results of botulinum toxin injections can
e analysed quantitatively according to the disease respon-
ible for drooling and according to the injection protocol
sed.
Protocol 6 (only one injection of 25mU per gland) was
referred in children with small salivary glands to avoid
ny risk of injection beyond the gland. This protocol was
ffective in 77.7% of cases. With this protocol, the vol-
mes injected were proportionally greater than those used
n adults, due to the smaller size of the salivary glands,
uggesting that the use of a larger volume of the same
oncentration in adults could possibly improve the efﬁcacy
f these injections.
sease and the protocol.
P3 P4 P5 P6
) (24) (2) (7) (15)
7% 57% 0% 0% —
80% — — 100%
83.3% — 100% 77.7%
0% — — 100%
6% 50% 0% — 100%
% 0% — — 100%
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Table 4 Published studies conducted between 1997 and 2007, including more than 10 patients.
Authors n/disease Guidance Evaluation Efﬁcacy
Dogu 2004 [15] 15/Parkinson Ultrasound vs
anatomical
Cotton rolls
VAS 0 to 100
4.4months
Ellies 2004 [18] 33/varied Ultrasound Sialometry 3 to 7months
Ellies 2003 [13] 13/varied Ultrasound Clinical
Salivary
ultrasound
4 to 7months
Friedman 2001 [19] 11/Parkinson Anatomical Cotton rolls
Jongerius 2004 [4,17] 45/Cerebral
palsy
Ultrasound VAS, DQ 6months
Lipp 2003 [20] 30/varied Anatomical Cotton rolls
Counter
Questionnaire
1 to 6 months
Mancini 2003 [21] 20/Parkinson Ultrasound DRS
Questionnaire
1months
Marks 2001 [22] 28/Parkinson DRS
Saliva collected
1 to 5 months
Nobrega 2007 [23] 21/Parkinson Ultrasound DRS
Ondo 2004 [24] 16/Parkinson Anatomical DRS
Questionnaire
Scintigraphy
3 to 5months
Porta 2001 [15] 10/varied Ultrasound VAS 4 to 7months
Savarese 2004 [25] 23/Cerebral
palsy
Anatomical VAS 2months
Suskind 2002 [26] 17/Cerebral
palsy
Ultrasound Cotton rolls
DQ
Questionnaire
1 to 8months
Wan 2005 [27] 58/varied 2months
Kalf 2007 [3] 17/Parkinson Ultrasound DRS
Gerlinger 2007 [28] 21/Cerebral
palsy
Ultrasound 3months
Contarino 2007 [5] 9/Parkinson
9/ALS
Ultrasound Cotton rolls 1 to 6months
Verma 2006 [29] 10/ALS VAS
Questionnaire
3months
Su 2006 [30] 15/Parkinson Cotton rolls 4months
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In 10 patients with various chronic neurological diseases,
including four patients with ALS, Porta et al. [15] reported
an efﬁcacy of botulinum toxin injections for four to seven
months. The present series comprised a large number of
patients with ALS (n = 25), in whom only protocol 2 was effec-
tive in 68.7% of cases. Pal et al. [16] reported an efﬁcacy
of 66% for botulinum toxin injections in nine patients with
Parkinson’s disease, while, in the present series, protocol 2
was effective in 77% of patients with this disease (13% partial
efﬁcacy and 64% good efﬁcacy).
Protocol 2 was the protocol most frequently used in this
study, based on the efﬁcacy of the other protocols and pub-
lished data. This protocol was most effective in Parkinson’s
disease, but the global efﬁcacy (partial and good) remained
relatively constant regardless of the disease responsible for
drooling, ranging from 68.7% to 100%. This protocol, which
consists of a single injection of 20mU into each submax-
illary gland and two injections of 15mU into each parotid
o
c
f
rDRS
land, was the most effective of the seven protocols used
n this study, with an efﬁcacy of 72%. In line with Jongerius
t al. [17], it therefore appears legitimate to perform a sin-
le injection of a relatively large dose into the submaxillary
lands and two injections into the parotid gland.
The loss of efﬁcacy of botulinum toxin at the synapse, to
hich it is permanently bound, is due to axon regrowth. This
henomenon partly explains recurrence of drooling symp-
oms some time after treatment, which may require another
njection session. Among the patients treated by several
njection sessions (n = 38 patients), efﬁcacy appeared to
lobally increase with the number of injections.
Evaluation of the efﬁcacy of botulinum toxin injec-
ion cannot be based on objective parameters, as an
bjective reduction of saliva ﬂow rate is not necessarily
orrelated with improvement of drooling and patient com-
ort. The methods of objective quantiﬁcation show poor
eproducibility from one patient to another and do not
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ake into account circadian ﬂuctuations of saliva ﬂow rate.
t therefore appears preferable to use simple, subjective
ethods, based on clinical interview of the patient or the
atient’s family. In this series, all patients were asked, six to
ight weeks after treatment, about their overall satisfaction
nd their desire to repeat injection sessions and not about
possible reduction of the saliva ﬂow rate.
However, a marked disparity of efﬁcacy was observed
nd it is difﬁcult to quantitatively evaluate the patient’s
lobal impression that ranged from complete satisfaction
o total inefﬁcacy of injections, despite the use of a stan-
ard protocol. No reliable explanation can be proposed for
his phenomenon, which probably has a multifactorial ori-
in, including a placebo effect on the postural disorders and
isorders of deglutition responsible for drooling, which are
ot modiﬁed by reduction of saliva ﬂow rate.
onclusion
rooling is a common symptom associated with
eurodegenerative diseases, cerebral palsy and many
iseases causing postural disorders and disorders of deg-
utition. The present series, comprising 70 patients, is the
argest series since the introduction of botulinum toxin
njections for the treatment of drooling. It clearly demon-
trates the efﬁcacy of these injections on the patient’s
uality of life, making botulinum toxin injection the treat-
ent of choice for drooling. The various studies published
n the literature are difﬁcult to compare in view of the very
ariable doses, injection techniques and diseases treated.
his study has the advantage of using various injection
rotocols in a large number of patients with various diseases
o determine the most effective injection sites and doses.
n this study, the efﬁcacy on quality of life appeared to be
ependent on the dose injected into the submaxillary gland
nd was independent of the characteristics of parotid gland
njections. We therefore propose two injections of 15mU
nto each parotid gland and one injection of 20mU into
ach submaxillary gland with ultrasound guidance.
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